Medication adherence boosts biometric outcomes in diabetic patients
October 29th 2015For patients with diabetes or high blood cholesterol, greater medication adherence is associated with a greater likelihood that the patient will achieve target biometric A1c and low-density lipoprotein levels, respectively, according to a poster session presented at the Academy of Managed Care Pharmacy meeting.
Read More
FDA approves new treatment for pancreatic cancer
October 26th 2015The FDA approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy.
Read More
FDA approves Veltassa to treat hyperkalemia
October 26th 2015FDA approved patiromer (Veltassa, Relypsa) oral suspension for the treatment of hyperkalemia. Hyperkalemia is the condition when blood potassium levels are higher than normal in the kidneys, which can lead to abnormal heart rhythms or sometimes death.
Read More
Study: Members not following updated statin therapy guidelines
October 26th 2015Prime Therapeutics conducted a study to estimate how many commercial members have ASCVD, but are not being treated with high-intensity statin therapy, as recommended in the 2013 ACC/AHA cholesterol guidelines. View the results.
Read More
FDA approves orphan drug for bleeding disorder
October 21st 2015The FDA this week approved Coagadex, Coagulation Factor X (Human) for hereditary Factor X (10) deficiency. Until the new orphan drug approval, no specific coagulation factor replacement therapy was available for patients with hereditary Factor X deficiency.
Read More
[BLOG]: Diagnostics as aids for specialty drug treatment
October 21st 2015Laboratory diagnostics are essential tools of physician practice, informing many medical decisions. Physicians will increasingly rely on companion and other types of lab diagnostics that consider genetic, proteomic, or other markers in connection with drug treatment strategies.
Read More